Trials / Completed
CompletedNCT04282746
A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants
An Open-label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to characterize the plasma pharmacokinetic (PK) profile following the single ascending dose (SAD) levels of an (S)-ketamine oral solution for sublingual administration in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-54135419 | Single dose of JNJ-54135419 oral solution will be administered sublingually. |
Timeline
- Start date
- 2020-02-18
- Primary completion
- 2020-08-11
- Completion
- 2020-08-17
- First posted
- 2020-02-25
- Last updated
- 2025-04-27
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04282746. Inclusion in this directory is not an endorsement.